+91-9660032889
+91-9660032889
support@mysiponline.com
-
₹115.49
(0.6%)
Current NAV 22-04-2025
-
7.26%
Returns
-
Min. SIP ₹500
Min. Investment ₹5000
Fund Suitability Test
Returns (NAV as on 22-Apr-2025)
Track investment returns to meet financial goals.
| This Fund | Category Avg. | Benchmark | |
|---|---|---|---|
| 1W | 2.65% | 4.18% | 2.37% |
| 1M | 1.27% | 0% | 0% |
| 3M | -8.15% | -4.87% | -3.71% |
| 6M | -11.31% | -6.1% | 0% |
| 1Y | 7.26% | 18.65% | 0% |
| 2Y | 21.46% | 33.2% | 0% |
| 3Y | 12.75% | 18.77% | 0% |
| 5Y | 15.23% | 22.45% | 0% |
| ALL | 12.42% | 19.08% | 0% |
Check out what are trailling and rolling returns of this fund ?
View Detail Return Analysis1 Lac Users Opted for this Service
Free KYC Check
To know your eligibility for Mutual Fund Investment
Risk Analysis
| Standard Dev | Sharpe | Beta | Alpha | |
|---|---|---|---|---|
| Fund | 15.73% | 0.67% | 0.92% | -0.11% |
| Category | 16.58% | 0.7% | 0.7% | 0.7% |
Riskometer
Comparison Of Nippon India Pharma Fund - IDCW Option
Compare your fund with the top category schemes.
Tata Liquid Fund -Regular Plan - Growth Option
3Y Returns6.75% (p.a.)
Mirae Asset Liquid Fund - Growth
3Y Returns6.8% (p.a.)
Invesco India Dynamic Equity Fund - Growth
3Y Returns12.29% (p.a.)
Nippon India Balanced Advantage Fund-Growth Plan-Bonus Option
3Y Returns11.83% (p.a.)
Axis Conservative Hybrid Fund - Regular Plan - Growth Option
3Y Returns7.12% (p.a.)
SBI Conservative Hybrid Fund - Regular Plan - Growth
3Y Returns9.87% (p.a.)
SBI Gold Fund Regular Plan - Growth
3Y Returns21.88% (p.a.)
Aditya Birla Sun Life Gold Fund-Growth
3Y Returns21.86% (p.a.)
SIP Returns Calculator
A simple tool to calculate your SIP returns.
- Invested Amount
- Estimated Returns
- Future Value
Start small, dream big: Begin your journey to long-term wealth with SIPs starting at just ₹1000!
Start SIPPortfolio Summary (as on 31-Jan-2025)
An insight into your portfolio composition.
Equity98.64% Others1.36%
Equity Market Cap
Top 5 Sectors of Equity
Healthcare 99%
Top 5 Companies of Equity
Sun Pharmaceuticals Industries Ltd 14%
Divi's Laboratories Ltd 9%
Lupin Ltd 8%
Cipla Ltd 6%
Dr Reddy's Laboratories Ltd 5%
Others Market Cap
Top 5 Sectors of Others
1%
Top 5 Companies of Others
Triparty Repo 1%
Cash Margin - Ccil 0%
Net Current Assets -0%
Check out the favourite sectors and companies of this fund
Detail Portfolio AnalysisAlternative Fund Category Peer View
Check out the other Mutual Funds in this category
More Funds From Nippon Mutual Fund
| Scheme Name | 1M | 3M | 6M | 1Y | 5Y | |
|---|---|---|---|---|---|---|
| Nippon India Gold Savings Fund-Growth plan- Growth Option | 12.07% | 22.49% | 25.89% | 33.78% | 13.82% | |
| Nippon India Banking and Financial Services Fund-Growth Plan-Growth Option | 9.25% | 14% | 7.66% | 19.2% | 29.81% | |
| Nippon India Pharma Fund-Growth Plan-Growth Option | 1.27% | 0.33% | -3.12% | 17.17% | 22.35% | |
| Nippon India Nifty Bank Index Fund - Reg (G) | 9.84% | 13.89% | 8.01% | 15.99% | 0% | |
| Nippon India Asset Allocator FoF - Regular Plan - Growth Option | 4.74% | 6.51% | 3.99% | 15.17% | 0% | |
| Nippon India Growth Fund-Growth Plan-Growth Option | 4.67% | 2.41% | -4.52% | 15.07% | 33.74% |
Take test again
Chat with usFrequently Asked Questions
What is the current NAV of Nippon India Pharma Fund - IDCW Option?
Net asset value is the per unit price of the mutual fund. The NAV of funds changes every day. The latest NAV of Nippon India Pharma Fund - IDCW Option as of 22-04-2025 is 115.4866.
What is the benchmark of Nippon India Pharma Fund - IDCW Option?
Nippon performance is primarily benchmarked against the NIFTY 500 TRI with NIFTY 50 TRI serving as an addition.
Is Nippon India Pharma Fund - IDCW Option a safe fund to invest?
Every fund has different types of risk which are mentioned in the risko-meter. The investors are advised to understand their risk tolerance and decide which type of fund they can invest in.
What are the top 5 holdings of Nippon India Pharma Fund - IDCW Option?
The fund's top 5 sectors holdings are Healthcare,
How can I redeem my investments in Nippon India Pharma Fund - IDCW Option?
Redeeming your investments in Nippon India Pharma Fund - IDCW Option is super easy.
• If you have invested this fund via MySIPonline, just log into the app, go to the investment section, and place your redemption request.
• If you have invested this fund from elsewhere, go to the fund house website and place your redemption request from there.
Who manages this fund, and what is their expertise?
Sailesh Raj Bhan, with an extensive experience of 15 years while managing equity & related investments. He is focused on picking quality companies and holds them for a long duration to generate good compounding returns in their funds.
What is the expense ratio of Nippon India Pharma Fund - IDCW Option?
The expense ratio of a mutual fund means the charges that you pay to the mutual fund company for managing your investments in the fund. This fund has an expense ratio of 1.37%.
What is the AUM or size of Nippon India Pharma Fund - IDCW Option?
AUM or asset under management is the total value of the assets held by a mutual fund scheme. A fund with a high AUM means a lot of money has been invested in it. The AUM of Nippon India Pharma Fund - IDCW Option is Rs 8160.74 Crs. Crs.
Should I invest in Nippon India Pharma Fund - IDCW Option?
This fund has a consistency rating of which indicates that the fund has generated average returns. However, whatever returns that the fund delivers, it does so with exceptional consistency. You can consider this fund if the predictability of returns is what you are looking for.
How to start online SIP in Nippon India Pharma Fund - IDCW Options?
MySIPonline is a dedicated platform to start online SIP or mutual funds in any scheme of mutual funds. Firstly, the investor needs to complete KYC details, choose the best fund, add it to the cart, and make the payment through UPI, net banking, or debit card available on our site.
Is there any brokerage/advisory fees on Mutual Fund SIP transactions?
At MySIPonline, we do not charge any fees related to brokerage & advisory part. That makes us more accessible and cost-effective for a broader range of investors.
